{
    "clinical_study": {
        "@rank": "70570", 
        "arm_group": {
            "arm_group_label": "AMG 386 15mg/kg and paclitaxel 80mg/m2", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone\n      and in combination with AMG 386  to determine whether AMG 386 alters the pharmacokinetics of\n      paclitaxel"
        }, 
        "brief_title": "AMG 386 Drug-Drug Interaction Study With Paclitaxel", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "detailed_description": {
            "textblock": "Eligible subjects enrolled in the study will begin receiving paclitaxel on a three weeks on\n      / one week off schedule at study day 1 and weekly AMG 386 beginning at study day 8. The\n      pharmacokinetic portion of the study occurs during the first two study cycles with intensive\n      PK collections on study weeks 1, 6 and 8. Once the pharmacokinetic assessment period is\n      completed, continued combination therapy with AMG 386 and paclitaxel or single-agent AMG 386\n      will be administered at the investigator's discretion until progression, unacceptable\n      toxicity develops, or study withdrawal."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men or women \u2265 18 years of age\n\n          -  Have a pathologically documented, and definitely diagnosed, advanced solid tumor that\n             is refractory to standard treatment, or for which no curative therapy is available\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n\n          -  Normal or clinically acceptable ECG (12 lead reporting PR, QRS, QTc)\n\n        Exclusion Criteria:\n\n          -  Subjects with gastric cancer or any malignancy with purely squamous cell histology\n\n          -  Known history of primary central nervous system (CNS) tumors or CNS metastases\n\n          -  Myocardial infarction within 1 year before study day 1, unstable or uncontrolled\n             disease/condition related to or affecting cardiac function\n\n          -  History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year\n             before study day 1\n\n          -  A baseline ECG QTc interval > 450 msec\n\n          -  Active grade 2 or greater peripheral vascular disease\n\n          -  History of pulmonary hemorrhage or gross hemoptysis within 6 months before study day\n             1\n\n          -  Non-healing wound, ulcer (including gastrointestinal) or fracture\n\n          -  Known positive test for human immunodeficiency virus infection, or active hepatitis B\n             or hepatitis C infection\n\n          -  Major surgery within 1 month before study day 1\n\n          -  Concurrent antitumor treatment within 4 weeks (6 weeks for nitrosoureas or mitomycin)\n             before study day 1\n\n          -  Unable to tolerate IV administration or repeated blood withdrawal\n\n          -  Hypersensitivity to paclitaxel or drugs using the vehicle cremophor\n\n          -  Known sensitivity to mammalian-derived products, bacterially-produced proteins, or\n             any of the products to be administered during dosing\n\n          -  Chronic neuropathy grade \u2265 1\n\n          -  Concurrent or prior treatment with 2C8 and 3A4 substrates\n\n          -  Enrolled in or has not yet completed at least 30 days (prior to study day 1) since\n             ending other investigational device or drug, or currently receiving other\n             investigational treatment.\n\n          -  Men and woman of reproductive potential, unwilling to practice a highly effective\n             method of birth control for the duration of the study and an additional 6 months\n             after the last dose of AMG 386\n\n          -  Women who are lactating/breastfeeding\n\n          -  Women with a positive pregnancy test\n\n          -  Women planning to become pregnant during the duration of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992341", 
            "org_study_id": "20101151"
        }, 
        "intervention": [
            {
                "arm_group_label": "AMG 386 15mg/kg and paclitaxel 80mg/m2", 
                "description": "Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.", 
                "intervention_name": "AMG 386", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }, 
            {
                "arm_group_label": "AMG 386 15mg/kg and paclitaxel 80mg/m2", 
                "description": "Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "sarcomas", 
            "carcinomas"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "University of Colorado Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "University of Utah Huntsman Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Pharmacokinetic Drug-Drug Interaction (DDI) Study of AMG 386 in Combination With Paclitaxel in Adult Subjects With Advanced Solid Tumors", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Paclitaxel PK parameters with and without the co-administration of AMG 386.", 
            "measure": "Paclitaxel PK parameters", 
            "safety_issue": "Yes", 
            "time_frame": "9 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992341"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AMG 386 PK steady state PK parameters with and without paclitaxel co-administration", 
                "measure": "AMG 386 PK parameters", 
                "safety_issue": "Yes", 
                "time_frame": "9 weeks"
            }, 
            {
                "description": "Subject incidence of treatment-emergent adverse events: Assessments include physical examinations, vitals, clinical laboratories, and electrocardiograms (ECG) \u2022 Results of safety laboratory tests, vital sign measurements, and ECG measurments", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Average of 6 months"
            }, 
            {
                "description": "Incidence of anti-AMG 386 antibody formation", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Average of 6 months"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}